Immunotherapy for locally advanced and metastatic basal cell carcinoma: a narrative review
Authors:
- Xiaoqing LiXLXiaoqing Li
- Hongru WangHWHongru Wang
- Qingli LuQLQingli Lu
Open Access
- 1 November 2024
- journal article
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (11) , 6565-6575
Abstract
Basal cell carcinoma (BCC) is the most common malignancy of humankind, characterized by its low propensity for metastasis and its high recurrence rate. Surgical intervention is the predominant therapeutic approach. However, for cases of locally advanced BCC (laBCC) and metastatic BCC (mBCC), systematic therapy may be the first option. In recent years, tumor immunotherapy has garnered significant attention within the scientific community. And it has progressively demonstrated its efficacy in the treatment of laBCC and mBCC. This review aims to summarize the characteristics of immune microenvironment, biomarkers, and immunotherapies of BCC, and provide a reference for further research on BCC immunotherapy. We searched literature in PubMed database and Web of Science and considered all study types written in English from 2013 to 2024. The alteration of the immune microenvironment is a pivotal factor in the progression of BCC. The expression levels of sex determining region Y (SRY)-box 2 (SOX2) and matrix metalloproteinases (MMPs) have emerged as potential prognostic biomarkers for BCC. And they are promising therapeutic targets for laBCC and mBCC. For patients presenting with laBCC or mBCC, a spectrum of immunotherapeutic approaches is being explored, including inhibition of the programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1), blockade of cytotoxic T-lymphocyte antigen 4 (CTLA-4), lymphocyte activation gene 3 (LAG-3) inhibition therapy, the use of chimeric antigen receptor (CAR)-T cells, and vaccination. Cemiplimab is the first immune checkpoint inhibitor (ICI) approved by the Food and Drug Administration for refractory BCC, marking a major breakthrough in BCC immunotherapy. Immunotherapies have shown efficacy in clinical studies. In the future, more multicenter studies with large samples are needed to further explore the efficacy and safety of immunotherapy for BCC.Keywords
This publication has 70 references indexed in Scilit:
- Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment ModalitiesJAMA Dermatology, 2017
- Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell CarcinomaJAMA Dermatology, 2017
- Immunosuppressive Environment in Basal Cell Carcinoma: The Role of Regulatory T CellsActa Dermato-Venereologica, 2016
- Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapynpj Genomic Medicine, 2016
- Anti‐programmed cell death‐1 therapy in nonmelanoma skin cancerBritish Journal of Dermatology, 2016
- Expression of metalloproteinases (MMP-2 and MMP-9) in basal-cell carcinomaMolecular Biology Reports, 2016
- Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanomaJAAD Case Reports, 2016
- Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cellsCytokine, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignanciesJournal of Hematology & Oncology, 2013